Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR1 | Q92633 | 13/20 | 0.73 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | LPAR3 | Q9UBY5 | 4/20 | 0.46 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.41 |
| ▸ | GRM5 | P41594 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12989052 | 1.00 | LPAR1 (0.73) | LPAR1MEN1KMT2ALPAR3LPAR2 | |
| SCHEMBL12990132 | 0.86 | LPAR1 (0.86) | LPAR1LPAR3LPAR2 | |
| SCHEMBL12989765 | 0.84 | LPAR1 (1.00) | LPAR1LPAR3LPAR2 | |
| SCHEMBL12988949 | 0.83 | LPAR1 (0.72) | LPAR1MEN1KMT2ALPAR3 | |
| SCHEMBL12989367 | 0.83 | LPAR1 (0.72) | LPAR1MEN1KMT2ALPAR3 | |
| SCHEMBL23384065 | 0.83 | LPAR1 (0.62) | LPAR1LPAR3LPAR2 | |
| SCHEMBL29948360 | 0.83 | LPAR1 (0.62) | LPAR1LPAR3LPAR2 | |
| SCHEMBL17083236 | 0.82 | LPAR1 (1.00) | LPAR1LPAR3LPAR2 | |
| SCHEMBL17077077 | 0.82 | LPAR1 (1.00) | LPAR1LPAR3LPAR2 | |
| SCHEMBL17083219 | 0.82 | LPAR1 (1.00) | LPAR1LPAR3LPAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12428430-B2 | Oxabicyclo acids as LPA antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-09-30 | — | — | US | disclosed |
| US-11980609-B2 | LPA receptor antagonists and uses thereof | GILEAD SCIENCES, INC. (US) | 2024-05-14 | — | — | US | disclosed |
| EP-4337641-A1 | LPA RECEPTOR ANTAGONISTS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2024-03-20 | — | — | EP | disclosed |
| EP-3853232-B1 | OXABICYCLO ACIDS AS LPA ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2023-03-01 | — | — | EP | disclosed |
| US-20220411405-A1 | LPA RECEPTOR ANTAGONISTS AND USES THEREOF | GILEAD SCIENCES, INC. | 2022-12-29 | — | — | US | disclosed |
| WO-2022240879-A1 | LPA RECEPTOR ANTAGONISTS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2022-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12428430-B2 | Oxabicyclo acids as LPA antagonists | LPAR1, LPAR2, LPAR3 | LPAR1 1/4885MEN1 3637/4885KMT2A 3689/4885 |
| US-11980609-B2 | LPA receptor antagonists and uses thereof | LPAR1, LPAR2, LPAR4 | LPAR1 1/4885MEN1 4641/4885KMT2A 2043/4885 |
| US-20220411405-A1 | LPA RECEPTOR ANTAGONISTS AND USES THEREOF | LPAR1, LPAR2, LPAR4 | LPAR1 1/4885MEN1 4641/4885KMT2A 2043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.